The Lung Master Protocol (Lung-MAP)
By Vassiliki A. Papadimitrakopoulou, MD
Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...
Q & A with Yi-Long Wu, MD
What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?
Posted: October 2017
Current Chinese Lung...
Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...
Posted: June 2017
By David Planchard, MD, PhD
What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC?
Recently, progress has been made in characterization...
ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer
By Heather Wakelee, MD
Posted: October 2017
For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with...
Uncommon Oncogenic Drivers in NSCLC
By Karen L. Reckamp, MD, MS
Posted: March 1, 2019
Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease....
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...
By Julien Mazieres, MD, PhD
Posted: October 2017
The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The...
Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to Osimertinib and Other...
By Denis Moro-Sibilot, MD, MSc
Posted: April 16, 2020
EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of...
Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios
By D. Ross Camidge, MD, and Mary W. Redman, PhD
Posted: August 2018
Updates of the primary analysis of the phase III ALEX trial were presented...
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
By Ben Solomon, MBBS, PhD, FRACP
Posted: August 19, 2020
ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur...
ALK Testing in Europe
By Enriqueta Felip, MD, PhD
Posted: February 2018
ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with...
